SCHEMBL2637280

SCHEMBL2637280

CC1=N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)C[C@@H]2O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OGA O60502 19/20 1.00
SI P14410 1/20 0.35
HEXA P06865 1/20 0.33
HEXB P07686 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15061582 1.00 OGA (1.00) OGASIHEXAHEXB
SCHEMBL2637452 1.00 OGA (1.00) OGASIHEXAHEXB
SCHEMBL13321843 1.00 OGA (1.00) OGASIHEXAHEXB
SCHEMBL13353993 1.00 OGA (1.00) OGASIHEXAHEXB
SCHEMBL2637378 0.81 OGA (0.68) OGASI
SCHEMBL2637380 0.81 OGA (0.68) OGASI
SCHEMBL2637409 0.80 OGA (0.67) OGASI
SCHEMBL2637320 0.80 OGA (0.67) OGASI
SCHEMBL2637505 0.80 OGA (0.67) OGASI
SCHEMBL2637701 0.80 OGA (0.66) OGASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131044-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF SIMON FRASER UNIVERSITY (CA) 2013-05-23 US claimed
EP-2569291-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF Simon Fraser University (CA) 2013-03-20 EP claimed
WO-2011140640-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF SIMON FRASER UNIVERSITY (CA) 2011-11-17 WO claimed
EP-2569291-B1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF UNIV FRASER SIMON (CA) 2016-04-06 EP disclosed
EP-2569291-B1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF UNIV FRASER SIMON (CA) 2016-04-06 EP disclosed
US-9120781-B2 Selective glycosidase inhibitors and uses thereof SIMON FRASER UNIVERSITY (CA) 2015-09-01 US disclosed
US-9120781-B2 Selective glycosidase inhibitors and uses thereof SIMON FRASER UNIVERSITY (CA) 2015-09-01 US disclosed
US-9120781-B2 Selective glycosidase inhibitors and uses thereof SIMON FRASER UNIVERSITY (CA) 2015-09-01 US disclosed
US-20130131044-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF SIMON FRASER UNIVERSITY (CA) 2013-05-23 US disclosed
US-20130131044-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF SIMON FRASER UNIVERSITY (CA) 2013-05-23 US disclosed
US-20130131044-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF SIMON FRASER UNIVERSITY (CA) 2013-05-23 US disclosed
WO-2011140640-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF SIMON FRASER UNIVERSITY (CA) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131044-A1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF ENGASE, OGA, GALE OGA 2/4885SI 74/4885HEXA 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.